Literature DB >> 10946882

Familial dysalbuminemic hyperthyroxinemia in a Swiss family caused by a mutant albumin (R218P) shows an apparent discrepancy between serum concentration and affinity for thyroxine.

S Pannain1, M Feldman, U Eiholzer, R E Weiss, N H Scherberg, S Refetoff.   

Abstract

Familial dysalbuminemic hyperthyroxinemia (FDH), is the most common cause of inherited increase in serum total T4 (TT4) in the Caucasian population. It is caused by a mutation (R218H) in the human serum albumin (HSA) gene, resulting in 10-fold higher affinity for T4 and, in heterozygous affected subjects, a TT4 level 2-fold higher than that in subjects expressing the wild-type HSA only. We now report FDH in a Swiss family, caused by HSA R218P, previously reported in subjects of Japanese origin. In this form of FDH, serum TT4 levels are 14- to 20-fold the normal mean, confirmed by measurements in serum extracts. TrT3 and TT3, concentrations are 7- and 2-fold above the mean, respectively. Thus, to maintain a normal free T4 level, the calculated affinity constant (Ka) of HSA R218P should be about 16-fold higher than that of HSA R218H. Surprisingly, the Ka values measured at saturation were similar: 5.4 x 10(6) and 6.4 x 10(6) mol/L(-1) for HSA R218H, respectively. To determine how subjects with HSA R218P and R218P maintain a euthyroid state despite the markedly high serum TT4, the concentration of dialyzable T4 was measured at increasing amounts of TT4. At a TT4 level equivalent to that found in the subjects with HSA R218P, the absolute FT4 concentrations were 40, 432, and 1970 pmol/L for sera expressing HSAs R218P, R218H, and wild type, respectively. Thus, the affinity of HSA R218P for T4 must be higher than that of R218H to produce an 11-fold difference in FT4 at the same concentration ofTT4 This difference was obliterated at saturating concentrations of TT4 used for the determination of Ka values by the method of Scatchard.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946882     DOI: 10.1210/jcem.85.8.6746

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants.

Authors:  H Watanabe; U Kragh-Hansen; S Tanase; K Nakajou; M Mitarai; Y Iwao; T Maruyama; M Otagiri
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

2.  Familial dysalbuminemic hyperthyroxinemia in a 4-year-old girl with hyperactivity, palpitations and advanced dental age: how gold standard assays may be misleading.

Authors:  Abha Choudhary; Chutintorn Sriphrapradang; Samuel Refetoff; Zoltan Antal
Journal:  J Pediatr Endocrinol Metab       Date:  2015-01       Impact factor: 1.634

3.  High-performance frontal analysis of the binding of thyroxine enantiomers to human serum albumin.

Authors:  Tomoko Kimura; Keiko Nakanishi; Terumichi Nakagawa; Akimasa Shibukawa; Katsumi Matsuzaki
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

Review 4.  Clinical recognition and evaluation of patients with inherited serum thyroid hormone-binding protein mutations.

Authors:  M S Mimoto; S Refetoff
Journal:  J Endocrinol Invest       Date:  2019-07-27       Impact factor: 4.256

5.  A novel mutation in the Albumin gene (R218S) causing familial dysalbuminemic hyperthyroxinemia in a family of Bangladeshi extraction.

Authors:  Solomon Maximo Greenberg; Alfonso Massimiliano Ferrara; Everton S Nicholas; Alexandra M Dumitrescu; Vivian Cody; Roy E Weiss; Samuel Refetoff
Journal:  Thyroid       Date:  2014-03-21       Impact factor: 6.568

Review 6.  Inherited defects of thyroxine-binding proteins.

Authors:  Theodora Pappa; Alfonso Massimiliano Ferrara; Samuel Refetoff
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2015-09-30       Impact factor: 4.690

7.  Free Thyroxine Concentrations in Sera of Individuals with Familial Dysalbuminemic Hyperthyroxinemia: A Comparison of Three Methods of Measurement.

Authors:  Samuel Refetoff; Neal H Scherberg; Chao Yuan; William Wu; Zengru Wu; Michael J McPhaul
Journal:  Thyroid       Date:  2020-01       Impact factor: 6.568

8.  First Report of Familial Dysalbuminemic Hyperthyroxinemia With an ALB Variant.

Authors:  Yoon Young Cho; Ju Sun Song; Hyung Doo Park; Young Nam Kim; Hye In Kim; Tae Hyuk Kim; Jae Hoon Chung; Chang Seok Ki; Sun Wook Kim
Journal:  Ann Lab Med       Date:  2017-01       Impact factor: 3.464

Review 9.  Clinical, Genetic, and Protein Structural Aspects of Familial Dysalbuminemic Hyperthyroxinemia and Hypertriiodothyroninemia.

Authors:  Ulrich Kragh-Hansen; Monica Galliano; Lorenzo Minchiotti
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-01       Impact factor: 5.555

10.  A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia.

Authors:  Nadia Schoenmakers; Carla Moran; Irene Campi; Maura Agostini; Olivia Bacon; Odelia Rajanayagam; John Schwabe; Sonia Bradbury; Timothy Barrett; Frank Geoghegan; Maralyn Druce; Paolo Beck-Peccoz; Angela O'Toole; Penelope Clark; Michelle Bignell; Greta Lyons; David Halsall; Mark Gurnell; Krishna Chatterjee
Journal:  J Clin Endocrinol Metab       Date:  2014-03-19       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.